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Received October 26, 2015; accepted December 10, 2015AbstractBackground: Antituberculosis drug-induced liver injury (ATDILI) is a major safety concern for the treatment of tuberculosis (TB). The impact of
chronic hepatitis B infection (CHBI) on the risk of ATDILI is still controversial. In this study, we aimed to assess systematically the influence of
CHBI on the susceptibility to ATDILI.
Methods: We reviewed all English-language medical literature with the medical subject search headings hepatitis B and antitubercular agents
from the major medical databases. Thereafter, a systematic review and meta-analysis was performed on those publications that qualified.
Results: A total of 938 citations were retrieved on the initial major database search, from which 15 studies were determined to be eligible for
analysis. While undergoing anti-TB treatment, 575 cases with drug-induced liver injury (DILI) and 4128 controls without DILI were enrolled
into this analysis. The pooled odds ratio of all studies for the CHBI to ATDILI was 2.18 (95% confidence interval, 1.41e3.37). Among the
studies with a strict definition of DILI (alanine aminotransferase > 5  upper limit of normal value) and combination anti-TB regimen, the
impact of CHBI on ATDILI was significant only in the prospective studies (odds ratio, 3.41; 95% confidence interval, 1.77e6.59), but not in the
caseecontrol studies. However, in the studies with a strict definition of DILI and isoniazid only treatment, the association between CHBI and
ATDILI was not statistically significant.
Conclusion: This meta-analysis suggests that CHBI may increase the risk of ATDILI in the standard combination therapy for active TB. Close
follow-up and regular liver test monitoring are mandatory to treat TB in chronic hepatitis B carriers.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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There has been a resurgence of tuberculosis (TB) as a
public health burden and challenge arising from the increasing
prevalence of drug-resistant Mycobacterium tuberculosis
strains and patients with AIDS.1,2 The three common first-line
drugs for TB, isoniazid, rifampicin, and pyrazinamide, have
the potential to induce liver injury.1e4 This anti-TB drug-
induced liver injury (ATDILI) ranges from mild to severe
forms, and can even be fatal.1e4 The incidence of ATDILIsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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Fig. 1. Flow chart of the selection of eligible studies.
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injury, and ethnic populations. Generally, 10e20% of patients
may have elevated serum aminotransferase during the period
of treatment.13 Around 1% of patients may develop overt
hepatitis, defined as significant elevation of serum amino-
transferase, with jaundice or other clinical symptoms/signs.
The mortality rate of patients with overt hepatitis is estimated
to be around 10%.1e3 ATDILI is the most prevalent drug-
induced liver injury (DILI) in Taiwan, China, India, South
Africa, and many other areas, which can both threaten patients'
health and hinder the treatment of TB.1e3 Therefore, reason-
able attempts to militate against this hepatotoxicity are
important.
A better understanding of risk factors of ATDILI may assist
in the prevention and management of this crucial adverse drug
reaction.5,6 Elderly, Asian, malnutrition, alcoholism, chronic
hepatitis B and C infections, AIDS, pregnancy, coadminis-
tration of hepatotoxic agents, abnormal baseline liver function,
and genetic factors have been reported to increase the risk of
ATDILI.1e8 Chronic hepatitis B infection (CHBI) is prevalent
in Asia, and the interaction of CHBI and ATDILI has been a
concern for many decades. Some studies suggest CHBI mayincrease the incidence and severity of ATDILI.9e15 However,
many recent studies, most of them prospective studies from
Asia, have challenged this association.16e24 Based on the
earlier studies, the guidelines of anti-TB treatment in the USA,
Taiwan, and many other countries have regarded CHBI as a
risk factor, and suggested regular monitoring liver biochemical
tests in TB patients with CHBI before and during the period of
anti-TB treatment.4,25 This suggestion is based on the
assumption that CHBI may increase the risk of ATDILI.
However, all the relevant studies are small in sample size, with
inconsistent results. Currently, this crucial issue remains
controversial. We, therefore, performed a systematic review
and meta-analysis to examine the association between CHBI
and the risk of ATDILI.
2. Methods2.1. Identification and retrieval of studiesWe performed a search of Medline, PubMed, Embase, and
the Cochrane Database of Systemic Review for full-length
English language articles examining the association of
Table 1
Main characteristics of the 15 included studies in the order of publication year.
1st author, yref Publication
country
Race Sex (M/F) Age (y) mean ± SD Study design Sample size
(case/control)
Anti-TB
regimen
Main
diagnostic
criteria of
DILI
OR of DILI
in HBV
(95% CI)
HBV (þ) HBV () HBV (þ) HBV ()
McGlynn, 198614 USA Asian ND ND ND ND Prospective 20/361 Isoniazid ALT
> ULN
4.19
(1.66e10.55)*
Hwang, 199716 Taiwan Asian 6/3 40/14 40 ± 5 44 ± 2 Prospective 63/177 4 combination ALT
> ULN
1.17
(0.51e2.71)
Wong, 200010 Hong Kong Asian 33/10 171/105 45 ± 16 46 ± 19 Prospective 41/319 4 combination ALT
> 1.5 ULN
6.00
(2.85e12.62)*
Patel, 200211 USA Asian 61/42 23/20 ND ND Prospective 3/155 Isoniazid ALT
> 5 ULN
13.80
(0.70e272.2)
Fernandez-Villar,
200317
Spain Caucasian ND ND ND ND Prospective 20/402 Isoniazid ALT
> 5 ULN
1.11
(0.06e19.89)
Pan, 200515 China Asian ND ND ND ND Prospective 53/62 4 combination ALT
> 5 ULN
6.37
(2.18e18.62)*
Lee, 200518 Korea Asian 58/52 58/39 44 ± 15 44 ± 16 Caseecontrol 13/194 4 combination ALT
> 3 ULN
2.07
(0.62e6.95)
Sun, 200912 Taiwan Asian ND ND ND ND Prospective 48/228 4 combination ALT
> 5 ULN
3.89
(1.31e11.59)*
Chien, 201019 Taiwan Asian 19/6 173/97 61 ± 15 65 ± 20 Caseecontrol 28/292 4 combination ALT
> 5 ULN
1.54
(0.43e5.54)
Wang, 201113 Taiwan Asian 29/13 184/110 >65; 31% >65; 41% Prospective 64/314 4 combination ALT > 5 ULN 2.13
(0.99e4.56)
Chan, 201220 Taiwan Asian ND ND ND ND Prospective 5/158 Isoniazid ALT > 3 ULN 0.60
(0.03e11.34)
Shu, 201321 Taiwan Asian ND ND ND ND Caseecontrol 118/888 4 combination ALT > 5 ULN 0.68
(0.31e1.53)
Lomtadze, 201322 USA Caucasian ND ND ND ND Prospective 59/241 4 combination ALT > 2 ULN 3.31
(1.01e10.86)*
Shen, 201423 China Asian ND ND ND ND Caseecontrol 54/206 4 combination ALT > 3 ULN 1.99
(0.95e4.19)
Liu, 201424 Taiwan Asian 61/14 281/111 62 ± 15 69 ± 18 Caseecontrol 42/425 4 combination ALT > 5 ULN 0.64
(0.24e1.69)
*p < 0.05.
ALT ¼ alanine aminotransferase; CI ¼ confidence interval; DILI ¼ drug-induced liver injury; HBV(þ) ¼ hepatitis B virus carrier; HBV() ¼ non-hepatitis B
virus carrier; ND ¼ no data; OR ¼ odds ratio; TB ¼ tuberculosis; ULN ¼ upper limit of normal value.
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terms were hepatitis B/hepatitis B, chronic, and antituber-
cular agents. All databases were searched from their incep-
tion up to July 2015. Articles were selected for full text based
on title and abstract. Additionally, a manual search of the
bibliographies of retrieved publications was done to increase
the yield of potentially relevant articles. Two investigators
independently assessed the titles and abstracts of all retrieved
papers and assessed their eligibility for the study. Differences
in opinion were resolved by consensus with the other three
investigators.2.2. Inclusion and exclusion criteriaInclusion and exclusion criteria were defined at the time of
study conception and before data collection. For inclusion into
the meta-analysis, a study had to: (1) include patients with
anti-TB treatment; (2) recruit patients with or without ATDILI,
and with or without CHBI; and (3) be published as a full-
length article. We excluded studies: (1) without definition of
ATDILI; (2) involving patients with AIDS and undergoingantiretroviral therapy; (3) patients with autoimmune diseases
and taking immunomodulators, such as prednisolone, metho-
trexate, and tumor necrosis factor-a blockers. Studies included
in the analysis were reviewed for the following characteristics:
author and year of publication; ethnicity; prospective or
retrospective study; anti-TB regimen; and definition of
ATDLI.2.3. Statistical analysisThe odds ratio (OR) and 95% confidence interval (CI) for
the association of incidence of ATDLI and CHBI were
analyzed. The random effects model was applied for analyzing
the pooled data. Heterogeneity was tested by the between-
study variance using the I2 statistics with a cutoff of  50%,
and c2 test for Cochran Q statistics with p < 0.10. Subgroup
analysis was performed if heterogeneity existed, and funnel
plots were used to assess the extent of publication bias. All
statistical analyses were performed using the Review Manager
version 5.3.5 (RevMan for Windows, 2015; The Cochrane
Collaboration, Oxford, UK).
Fig. 2. Forest plot of association between chronic hepatitis B infection and the risk of antituberculosis drug-induced liver injury in all 15 studies. Events denote
patients with chronic hepatitis B infection. CI ¼ confidence interval; DILI ¼ drug-induced liver injury; M-H ¼ ManteleHaenszel.
Fig. 3. Funnel plot for the assessment of publication bias.
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A total of 938 citations were retrieved pursuant to the
initial search. After excluding unqualified papers, a total of
15 studies were included in the meta-analysis (Fig. 1). The
baseline characteristics of the included studies are reported in
Table 1. Overall, for patients who had undergone anti-TB
treatment, 575 patients with drug-induced liver injury
(DILI) and 4128 controls were enrolled into this study. A
total of 13 studies were based on the study of East Asian
patients, and only two studies focused on Caucasians (Table
1). Ten of the 15 studies were prospective studies, while five
were retrospective caseecontrol studies. Eleven of these
studies recruited patients with active TB, undergoing the
standard treatment of four-drug combination therapy, but four
studies focused on patients with latent TB and ongoing
isoniazid single-drug prophylactic treatment. Eight of the 15
studies adopted the major diagnostic criteria of DILI as
serum alanine aminotransferase (ALT) more than five times
the upper limit of normal value (ULN), which is a strict
definition of DILI.The OR of all included studies of the CHB status in the risk
of ATDILI was 2.18 (95% CI 1.41e3.37; Fig. 2). There was
significant heterogeneity among the studies (I2 ¼ 58%,
p ¼ 0.002).However, no significant publication bias was
detected by funnel plot (Fig. 3).
Among the studies utilizing the strict definition of DILI
(ALT > 5  upper limit of normal value) and combination
anti-TB regimen, the impact of CHBI on ATDILI was sig-
nificant only in the prospective studies (OR, 3.41; 95% CI,
1.77e6.59), but not in the caseecontrol studies (Fig. 4).
However, in the studies using the strict definition of DILI and
isoniazid-only treatment, the association between CHBI and
ATDILI was not statistically significant (Fig. 5).
4. Discussion
TB and CHBI may occur in the same individual, and it is
suspected that patients with CHBI may have an elevated risk
of ATDILI. This meta-analysis has shown that hepatitis B
virus (HBV) carriers have a predilection for ATDL in the
standard combination therapy to active TB.
Identification of high risk patients with ATDILI is crucial
in the prevention of this potentially fatal DILI. Several de-
cades ago, a few studies noted the association of CHBI and
ATDILI.9e15 One of those studies was our retrospective
investigation, which demonstrated that HBV carriers had a
higher incidence of ATDILI than noncarriers; also, it was
noted that HBV carriers with ATDILI had more severe liver
injury compared with noncarriers with ATDILI.9 Although
this study represented a pioneering undertaking in this field,
it was not included into this meta-analysis because the
CHB status data were not available in the non-ATDILI
group.9
One prospective study from Hong Kong highlights that the
incidence of liver dysfunction was significantly higher in HBV
carriers given anti-TB drugs (34.9%), compared with non-
carriers given anti-TB drugs (9.4%) and HBV carriers not
given anti-TB drugs (8.1%).10 After excluding patients with
Fig. 4. Odds ratio of chronic hepatitis B infection to antituberculosis drug-induced liver injury by the subgroup analysis of prospective studies and caseecontrol
studies in those with strict definition of DILI (ALT > 5 times the upper limit of normal value) and four-drug combination anti-TB regimen. Events denote patients
with chronic hepatitis B infection. CI ¼ confidence interval; DILI ¼ drug-induced liver injury; M-H ¼ ManteleHaenszel.
Fig. 5. Odds ratio of chronic hepatitis B infection to antituberculosis drug-induced liver injury by the subgroup analysis of different diagnostic criteria in those with
isoniazid only treatment. Events denote patients with chronic hepatitis B infection. CI ¼ confidence interval; DILI ¼ drug-induced liver injury; M-
H ¼ ManteleHaenszel.
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hepatitis B e antigen seroconversion, the first group still had a
high incidence of liver dysfunction (26.3%). After a review of
evidence derived from laboratory and histology data, they also
found that this group had more severe liver injury than the
other two control groups. Although this study could not
completely rule out the role of HBV flare-up in ATDILI, the
authors believed CHBI is an independent risk factor for this
hepatotoxicity.
However, it would appear that several recent studies have
discrepant results.16e24 The diverse HBV activity and liver
reserve in HBV carriers may influence the susceptibility and
severity of DILI. Positive serum hepatitis B e antigen
(HBeAg) and high HBV-DNA represent high activity andinfectivity of HBV, which may cause more hepatic damage to
the host. Under these circumstances, this cohort of HBV car-
riers may have less liver reserve to dispose of anti-TB drugs,
and thus render a higher incidence and severity of DILI. Patel
and Voigt11 first demonstrated that only the positive HBeAg
HBV carriers have a higher risk of ATDILI. Wang et al13
further showed that only the HBV carriers with high viral
load (HBV-DNA) have an increased susceptibility to ATDILI.
Therefore, it is plausible that the activity of HBV may play an
important role in the development of ATDILI. However, data
involving HBeAg and HBV-DNA are lacking in most of the
relevant studies. Further large scale control trials, including
information about HBV activity, are mandatory to corroborate
this association.
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However, in this meta-analysis, 13 studies involved the use of
Asian individuals, while only two studies focused on Cauca-
sians. Therefore, the minimal number of Caucasian studies
involved rendered meaningless any further analysis of the
impact of ethnicity.
However, this meta-analysis did further verify the reli-
ability of prospective cohort study (Fig. 4). It is possible that
the number of DILI cases may be underestimated, without
regular monitoring of liver tests in the caseecontrol studies.
The definition of DILI may affect study outcomes, and there
remains ongoing debate as to an adequate definition of DILI.
According to criteria from the Council for International
Organizations of Medical Sciences, ALT/aspartate trans-
aminase (AST) more than two times the level of ULN is
regarded as DILI.26 However, a mild increase of ALT/AST may
have no clinical significance. Elevation of ALT/AST more than
five times ULN, or more than three times ULN with jaundice,
was suggested as the inclusion criteria of DILI by the US DILI
Network.27,28 The higher threshold of ALT/ASTmay select real
DILI patients, who deserve further management, such as dis-
continuing or decreasing dose of discriminated drugs, close
monitoring liver function, and liver transplantation if necessary.
We adopted the strict diagnostic criteria of the DILI Network,
and found that the impact of CHBI on ATDILI was still sig-
nificant in the prospective studies with four-drug combination
therapy (Fig. 4). By contrast, in those studies using the strict
definition of DILI and isoniazid-only treatment, the association
between CHBI and ATDILI was not statistically significant. It is
reasonable to infer that the isoniazid-only therapy is less toxic
than the four-drug combination anti-TB regimen, which renders
the interaction with HBV insignificant.
The reason why HBV carriers have a higher risk of ATDILI
remains to be elucidated. However, several explanations have
been proposed, including a suspicion about reactivation of
HBV with flare-up hepatitis, and which has manifested with
high HBV-DNA and positive HBeAg in some patients as
mentioned.11,13 However, many HBV carriers with liver
dysfunction had negative HBeAg, and low or undetectable
HBV-DNA, whose hepatic damage could not be attributed to
HBV.10 In addition, in Wong et al's10 study, the HBV carriers
with anti-TB treatment still had a higher incidence of liver
injury than the HBV carriers without anti-TB therapy in the
same follow-up period. Therefore, reactivation of HBV can
only explain the cause of liver dysfunction in a portion of the
cases. Another possibility is that an improved immune system
due to TB infection control may lead to an attack on the
intrahepatocytic HBV.1 Additionally, in HBV carriers, liver
dysfunction may impair the metabolism of anti-TB drugs,
resulting in the accumulation of more toxic metabolites. In
addition to less liver reserve in HBV carriers, these metabo-
lites may easily further damage the liver. Furthermore, patients
with CHBI may have an upregulation of cytokines and a
mixed inflammatory response. This proinflammatory condition
triggered by replicating HBV may increase the susceptibility
to toxic metabolites from anti-TB drugs.11 However, the true
mechanism and interaction of HBV and anti-TB drugs inhepatotoxicity remains unknown, which requires further basic
study to elucidate.
The limitations of this meta-analysis are that we excluded
those studies focusing on patients with AIDS and autoimmune
disease, such as rheumatoid arthritis, systemic lupus erythe-
matosus, psoriasis, and Crohn's disease. Therefore, the
conclusion reached in this study could not be extrapolated
significantly to these other patient groups. The reason we
excluded AIDS patients is that these patients are always under
long-term antiretroviral therapy, which may also induce liver
injury. It is difficult to identify whether liver dysfunction is
caused by anti-retroviral agents, anti-TB drugs, or reactivation
of HBV. Similarly, the patients with autoimmune diseases may
have coadministration with many immuno-modulators or anti-
inflammatory drugs, such as prednisolone, methotrexate,
tumor necrosis factor-a blocker, sulfa drugs, and nonsteroid
anti-inflammatory drugs. All of these agents may induce liver
injury, and some of them may prompt HBV reactivation. To
avoid complexity and uncertainty, we excluded all of these
relevant papers. It may be possible to analyze these patient
groups when more studies are available in the future. The other
limitation of this meta-analysis is that all the studies could not
completely rule out the possibility of acute exacerbation of
CHBI in HBV carriers, alcoholic liver disease and nonalcoholic
fatty liver disease in the liver dysfunction, although the strict
diagnostic criteria of DILI may exclude some patients with
alcoholic liver disease and nonalcoholic fatty liver disease.
To prevent ATDILI, regular monitoring liver tests was
strongly suggested by the Center for Disease Control, Taiwan,
for all TB patients which included assaying liver biochemical
tests prior to anti-TB treatment, and at the 2nd week, 4th week,
and 8th week after treatment.25 Thereafter, the necessity and
frequency of monitoring will depend on the status of chronic
viral hepatitis infection and the clinical condition of the patients.
In the USA, monitoring of liver tests is recommended for high-
risk groups only, such as patients with chronic viral hepatitis
infection, AIDS, chronic ethanol consumption, and pregnant
women.4 This can be attributed to the relatively low incidence of
ATDILI in the USA, compared with that in Taiwan and many
other countries. A national 12-year case analysis in Taiwan
revealed that patients without liver test monitoring had more
severe liver injuries and poorer outcomes than thosewith regular
liver test monitoring.29 Since the present meta-analysis supports
the association of CHBI and ATDILI, we underline the impor-
tance of regularmonitoring of liver biochemical tests before and
during anti-TB treatment in HBV carriers.
In conclusion, this meta-analysis revealed that CHBI may
increase the risk of ATDILI in standard combination therapy
for active TB. Furthermore, our results underscore the
importance of close monitoring liver tests in HBV carriers
during anti-TB treatment.
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